JP2007505094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505094A5 JP2007505094A5 JP2006525899A JP2006525899A JP2007505094A5 JP 2007505094 A5 JP2007505094 A5 JP 2007505094A5 JP 2006525899 A JP2006525899 A JP 2006525899A JP 2006525899 A JP2006525899 A JP 2006525899A JP 2007505094 A5 JP2007505094 A5 JP 2007505094A5
- Authority
- JP
- Japan
- Prior art keywords
- protease
- target cell
- agonist
- fragment
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091005804 Peptidases Proteins 0.000 claims 20
- 239000004365 Protease Substances 0.000 claims 20
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 20
- 210000004027 cell Anatomy 0.000 claims 20
- 239000000556 agonist Substances 0.000 claims 16
- 238000000034 method Methods 0.000 claims 12
- 239000012634 fragment Substances 0.000 claims 9
- 231100000065 noncytotoxic Toxicity 0.000 claims 6
- 230000002020 noncytotoxic effect Effects 0.000 claims 6
- 230000028327 secretion Effects 0.000 claims 6
- 210000001163 endosome Anatomy 0.000 claims 5
- 230000005945 translocation Effects 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 210000000172 cytosol Anatomy 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000012202 endocytosis Effects 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 1
- 108010002231 IgA-specific serine endopeptidase Proteins 0.000 claims 1
- 108010055044 Tetanus Toxin Proteins 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 239000000700 radioactive tracer Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0321344.4A GB0321344D0 (en) | 2003-09-11 | 2003-09-11 | Re-targeted toxin conjugates |
| PCT/GB2004/003904 WO2005023309A2 (en) | 2003-09-11 | 2004-09-13 | Design of re-targeted toxin conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012026892A Division JP6122243B2 (ja) | 2003-09-11 | 2012-02-10 | リターゲティングされる毒素結合体の設計 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007505094A JP2007505094A (ja) | 2007-03-08 |
| JP2007505094A5 true JP2007505094A5 (enExample) | 2009-11-26 |
Family
ID=29226936
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006525899A Pending JP2007505094A (ja) | 2003-09-11 | 2004-09-13 | リターゲティングされる毒素結合体の設計 |
| JP2012026892A Expired - Lifetime JP6122243B2 (ja) | 2003-09-11 | 2012-02-10 | リターゲティングされる毒素結合体の設計 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012026892A Expired - Lifetime JP6122243B2 (ja) | 2003-09-11 | 2012-02-10 | リターゲティングされる毒素結合体の設計 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20070184048A1 (enExample) |
| EP (1) | EP1667725A2 (enExample) |
| JP (2) | JP2007505094A (enExample) |
| AU (1) | AU2004269979B2 (enExample) |
| CA (1) | CA2538619C (enExample) |
| GB (1) | GB0321344D0 (enExample) |
| WO (1) | WO2005023309A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| CA2380457A1 (en) | 1999-08-25 | 2001-03-01 | Allergan Sales, Inc. | Activatable recombinant neurotoxins |
| US7138127B1 (en) | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
| WO2006026780A1 (en) | 2004-09-01 | 2006-03-09 | Allergan, Inc. | Degradable clostridial toxins |
| GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US8778634B2 (en) | 2004-12-01 | 2014-07-15 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| US8399400B2 (en) | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
| US8603779B2 (en) | 2004-12-01 | 2013-12-10 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| CA2588292C (en) * | 2004-12-01 | 2019-01-15 | Health Protection Agency | Non-cytotoxic protein conjugates |
| GB0426397D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US8512984B2 (en) | 2004-12-01 | 2013-08-20 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| US7659092B2 (en) * | 2004-12-01 | 2010-02-09 | Syntaxin, Ltd. | Fusion proteins |
| CA2595115C (en) * | 2004-12-01 | 2014-01-21 | Health Protection Agency | Fusion proteins for treating, preventing or ameliorating pain |
| US8021859B2 (en) | 2005-03-15 | 2011-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| CA2601592A1 (en) | 2005-03-15 | 2006-09-28 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| DK1926744T4 (en) * | 2005-09-19 | 2019-01-28 | Allergan Inc | CLOSTRIDIUM TOXIN-ACTIVABLE CLOSTRIDIAL TOXINES |
| GB0610868D0 (en) * | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
| WO2008008803A2 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| AU2007347781B2 (en) | 2006-07-11 | 2013-10-03 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity |
| WO2009020748A2 (en) * | 2007-07-16 | 2009-02-12 | Avaxia Biologics, Inc. | Antibody therapy for modulating function of intestinal receptors |
| EP2725035A1 (en) | 2007-10-02 | 2014-04-30 | Avaxia Biologics, Inc. | Antibody therapy for use in the digestive tract |
| RU2010120016A (ru) * | 2007-10-23 | 2011-11-27 | Аллерган, Инк. (Us) | Способы лечения хронического нейрогенного воспаления с применением модифицированных клостридиальных токсинов |
| US10466245B2 (en) | 2008-02-20 | 2019-11-05 | The Secretary Of State For Health | Covalently linked thermostable kinase for decontamination process validation |
| GB0803068D0 (en) | 2008-02-20 | 2008-03-26 | Health Prot Agency | Cross-linked biological indicator |
| US8796216B2 (en) | 2008-06-12 | 2014-08-05 | Syntaxin Limited | Suppression of neuroendocrine diseases |
| EP2310029B1 (en) | 2008-06-12 | 2019-04-03 | Ipsen Bioinnovation Limited | Fusion proteins for use in the treatment of cancer |
| GB0820970D0 (en) * | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
| GB0903006D0 (en) * | 2009-02-23 | 2009-04-08 | Syntaxin Ltd | Modified non-cytotoxic proteases |
| JP5826635B2 (ja) | 2009-03-13 | 2015-12-02 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 免疫系調節エンドペプチターゼ活性アッセイ |
| US8420352B2 (en) * | 2009-08-27 | 2013-04-16 | Synaptic Research, Llc | Protein delivery system to generate pluripotent stem (iPS) cells or tissue specific cells |
| CA2784666A1 (en) | 2009-12-16 | 2011-11-17 | Allergan, Inc. | Modified clostridial toxins comprising an integrated protease cleavage site-binding domain |
| CA2788074C (en) | 2010-01-25 | 2016-07-12 | Allergan, Inc. | Methods of intracellular conversion of single-chain proteins into their di-chain form |
| JP6148979B2 (ja) | 2010-05-20 | 2017-06-14 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 分解性クロストリジウム毒素 |
| US20130330369A1 (en) | 2010-10-08 | 2013-12-12 | Allergan, Inc. | Reduction Of Antibody Response Against Botulinum Neurotoxin And Variants Thereof |
| GB201108108D0 (en) | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
| US20140056870A1 (en) * | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
| GB201219024D0 (en) * | 2012-10-23 | 2012-12-05 | Syntaxin Ltd | Assay |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| TW201814045A (zh) | 2016-09-16 | 2018-04-16 | 英商艾普森生物製藥有限公司 | 製造雙鏈梭狀芽孢桿菌神經毒素之方法 |
| JP7118055B2 (ja) | 2016-09-29 | 2022-08-15 | イプセン バイオファーム リミテッド | ハイブリッド神経毒 |
| EP3312290A1 (en) | 2016-10-18 | 2018-04-25 | Ipsen Biopharm Limited | Cellular vamp cleavage assay |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| CN112511569B (zh) * | 2021-02-07 | 2021-05-11 | 杭州筋斗腾云科技有限公司 | 网络资源访问请求的处理方法、系统及计算机设备 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL98528A0 (en) * | 1990-06-21 | 1992-07-15 | Merck & Co Inc | Pharmaceutical compositions containing hybrid for killing bladder cancer cells |
| GB9305735D0 (en) * | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
| GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| US6822076B2 (en) * | 1998-05-13 | 2004-11-23 | Biotecon Therapeutics Gmbh | Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof |
| AU755513B2 (en) * | 1998-05-13 | 2002-12-12 | Merz Pharma Gmbh & Co. Kgaa | Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof |
| GB9818548D0 (en) * | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
| KR100870123B1 (ko) * | 2000-10-20 | 2008-11-25 | 츄가이 세이야꾸 가부시키가이샤 | 저분자화 아고니스트 항체 |
| AU1091802A (en) * | 2000-10-20 | 2002-04-29 | Chugai Pharmaceutical Co Ltd | Degraded agonist antibody |
-
2003
- 2003-09-11 GB GBGB0321344.4A patent/GB0321344D0/en not_active Ceased
-
2004
- 2004-09-13 US US10/571,515 patent/US20070184048A1/en not_active Abandoned
- 2004-09-13 AU AU2004269979A patent/AU2004269979B2/en not_active Ceased
- 2004-09-13 CA CA2538619A patent/CA2538619C/en not_active Expired - Fee Related
- 2004-09-13 WO PCT/GB2004/003904 patent/WO2005023309A2/en not_active Ceased
- 2004-09-13 JP JP2006525899A patent/JP2007505094A/ja active Pending
- 2004-09-13 EP EP04768450A patent/EP1667725A2/en not_active Ceased
-
2009
- 2009-08-03 US US12/534,740 patent/US20090291457A1/en not_active Abandoned
-
2012
- 2012-02-10 JP JP2012026892A patent/JP6122243B2/ja not_active Expired - Lifetime
- 2012-06-20 US US13/528,762 patent/US20130122526A1/en not_active Abandoned
-
2018
- 2018-06-28 US US16/021,540 patent/US20180362951A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007505094A5 (enExample) | ||
| US12320813B2 (en) | Macromolecule analysis employing nucleic acid encoding | |
| Bayan et al. | Mycomembrane and S-layer: two important structures of Corynebacterium glutamicum cell envelope with promising biotechnology applications | |
| Chen et al. | Hydrophobic tagging-assisted N-termini enrichment for in-depth N-terminome analysis | |
| WO2006059105A3 (en) | Non-cytotoxic protein conjugates | |
| MX2011002567A (es) | Tecnologia de cromatografia liquida con espectrometria de masas y sus usos. | |
| WO2006059113A3 (en) | Fusion proteins comprising a non-cytotoxic protease, a targeting moiety, a protease cleavage site and a translocation domain | |
| JP2011503160A5 (enExample) | ||
| WO2010037836A3 (en) | Cross-species-specific psmaxcd3 bispecific single chain antibody | |
| WO2011010304A3 (en) | Method for preparing molecularly imprinted polymers and uses thereof | |
| JP2011512817A5 (enExample) | ||
| JP2018530315A5 (enExample) | ||
| Olinares et al. | A robust workflow for native mass spectrometric analysis of affinity-isolated endogenous protein assemblies | |
| Han et al. | Proteolysis and mass spectrometric analysis of an integral membrane: aquaporin 0 | |
| Schindler et al. | Aqueous polymer two-phase systems for the proteomic analysis of plasma membranes from minute brain samples | |
| CN102766214A (zh) | 含蛋白标签的sumo融合蛋白及其应用 | |
| Kalb et al. | Three enzymatically active neurotoxins of Clostridium botulinum strain Af84: BoNT/A2,/F4, and/F5 | |
| Zhang et al. | Probing SARS-CoV-2 membrane binding peptide via single-molecule AFM-based force spectroscopy | |
| Kang et al. | Isopeptide bonds in bacterial pili and their characterization by X‐ray crystallography and mass spectrometry | |
| Li et al. | Isolation of acetylated and free N-terminal peptides from proteomic samples based on tresyl-functionalized microspheres | |
| He et al. | Unique fragmentation of singly charged DEST cross-linked peptides | |
| Ruvkun et al. | Phylogenetic evidence for asparagine to aspartic acid protein editing of N-glycosylated SARS-CoV-2 viral proteins by NGLY1 deglycosylation/deamidation suggests an unusual vaccination strategy | |
| JP2003511087A5 (enExample) | ||
| AU2002358143A8 (en) | Method for determining molecule-molecule interaction in proteomics | |
| Upadhyay et al. | The Ubiquitin Tale: Current Strategies and Future Challenges |